Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1972 1
1979 2
1980 1
1981 1
1983 1
1985 2
1986 1
1988 3
1989 5
1990 1
1991 2
1992 2
1993 3
1994 1
1995 2
1996 2
1997 1
1998 2
1999 6
2000 2
2001 1
2002 6
2003 7
2004 8
2005 11
2006 5
2007 9
2008 13
2009 9
2010 8
2011 8
2012 12
2013 14
2014 15
2015 15
2016 16
2017 27
2018 18
2019 27
2020 28
2021 39
2022 33
2023 29
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

388 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for P. morozova
Search for P. Orozova instead (1 results)
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. McMurray JJ, et al. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30. N Engl J Med. 2014. PMID: 25176015 Free article. Clinical Trial.
At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). A total of 711 pati …
At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the …
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, Mastrandrea LD, Prabhu N, Arslanian S; NN8022-4180 Trial Investigators. Kelly AS, et al. N Engl J Med. 2020 May 28;382(22):2117-2128. doi: 10.1056/NEJMoa1916038. Epub 2020 Mar 31. N Engl J Med. 2020. PMID: 32233338 Clinical Trial.
Liraglutide was superior to placebo with regard to the change from baseline in the BMI standard-deviation score at week 56 (estimated difference, -0.22; 95% confidence interval [CI], -0.37 to -0.08; P = 0.002). A reduction in BMI of at least 5% was observed in 51 of 113 pa …
Liraglutide was superior to placebo with regard to the change from baseline in the BMI standard-deviation score at week 56 (estimated differ …
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.
Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG Jr, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH; TCGA Research Network; Noushmehr H, Iavarone A, Verhaak RG. Ceccarelli M, et al. Cell. 2016 Jan 28;164(3):550-63. doi: 10.1016/j.cell.2015.12.028. Cell. 2016. PMID: 26824661 Free PMC article.
The genetic landscape of high-risk neuroblastoma.
Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, Kim J, Lawrence MS, Lichenstein L, McKenna A, Pedamallu CS, Ramos AH, Shefler E, Sivachenko A, Sougnez C, Stewart C, Ally A, Birol I, Chiu R, Corbett RD, Hirst M, Jackman SD, Kamoh B, Khodabakshi AH, Krzywinski M, Lo A, Moore RA, Mungall KL, Qian J, Tam A, Thiessen N, Zhao Y, Cole KA, Diamond M, Diskin SJ, Mosse YP, Wood AC, Ji L, Sposto R, Badgett T, London WB, Moyer Y, Gastier-Foster JM, Smith MA, Guidry Auvil JM, Gerhard DS, Hogarty MD, Jones SJ, Lander ES, Gabriel SB, Getz G, Seeger RC, Khan J, Marra MA, Meyerson M, Maris JM. Pugh TJ, et al. Nat Genet. 2013 Mar;45(3):279-84. doi: 10.1038/ng.2529. Epub 2013 Jan 20. Nat Genet. 2013. PMID: 23334666 Free PMC article.
Genes with significant somatic mutation frequencies included ALK (9.2% of cases), PTPN11 (2.9%), ATRX (2.5%, and an additional 7.1% had focal deletions), MYCN (1.7%, causing a recurrent p.Pro44Leu alteration) and NRAS (0.83%). Rare, potentially pathogenic germline variants …
Genes with significant somatic mutation frequencies included ALK (9.2% of cases), PTPN11 (2.9%), ATRX (2.5%, and an additional 7.1% had foca …
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O'Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ; NAVIGATE ESUS Investigators. Hart RG, et al. N Engl J Med. 2018 Jun 7;378(23):2191-2201. doi: 10.1056/NEJMoa1802686. Epub 2018 May 16. N Engl J Med. 2018. PMID: 29766772 Free article. Clinical Trial.
The primary efficacy outcome occurred in 172 patients in the rivaroxaban group (annualized rate, 5.1%) and in 160 in the aspirin group (annualized rate, 4.8%) (hazard ratio, 1.07; 95% confidence interval [CI], 0.87 to 1.33; P=0.52). Recurrent ischemic stroke occurred in 15 …
The primary efficacy outcome occurred in 172 patients in the rivaroxaban group (annualized rate, 5.1%) and in 160 in the aspirin group (annu …
Lipid Alteration Signature in the Blood Plasma of Individuals With Schizophrenia, Depression, and Bipolar Disorder.
Tkachev A, Stekolshchikova E, Vanyushkina A, Zhang H, Morozova A, Zozulya S, Kurochkin I, Anikanov N, Egorova A, Yushina E, Vogl T, Senner F, Schaupp SK, Reich-Erkelenz D, Papiol S, Kohshour MO, Klöhn-Saghatolislam F, Kalman JL, Heilbronner U, Heilbronner M, Gade K, Comes AL, Budde M, Anderson-Schmidt H, Adorjan K, Wiltfang J, Reininghaus EZ, Juckel G, Dannlowski U, Fallgatter A, Spitzer C, Schmauß M, von Hagen M, Zorkina Y, Reznik A, Barkhatova A, Lisov R, Mokrov N, Panov M, Zubkov D, Petrova D, Zhou C, Liu Y, Pu J, Falkai P, Kostyuk G, Klyushnik T, Schulze TG, Xie P, Schulte EC, Khaitovich P. Tkachev A, et al. JAMA Psychiatry. 2023 Mar 1;80(3):250-259. doi: 10.1001/jamapsychiatry.2022.4350. JAMA Psychiatry. 2023. PMID: 36696101 Free PMC article.

Alterations were consistent between cohorts (CN and RU: [Pearson correlation] r = 0.75; DE-AT and CN: r = 0.78; DE-AT and RU: r = 0.82; P < 10-38). A lipid-based predictive model separated patients with SCZ from controls with high diagnostic ability (area under the rece

…
Alterations were consistent between cohorts (CN and RU: [Pearson correlation] r = 0.75; DE-AT and CN: r = 0.78; DE-AT and RU: r = 0.82; P …
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Bělohlávek J, Böhm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzàlez-Medina A, Hagège AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan Ö, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; PARADIGM-HF Investigators and Coordinators. Packer M, et al. Circulation. 2015 Jan 6;131(1):54-61. doi: 10.1161/CIRCULATIONAHA.114.013748. Epub 2014 Nov 17. Circulation. 2015. PMID: 25403646 Clinical Trial.
In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of medical treatment for heart failure (520 versus 604; hazard ratio, 0.84; 95% confidence interval, 0.74-0.94; P=0.003) or an emergency department visit for worsening heart fail …
In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of medical treatment for heart failure (520 v …
Persistence length of α-helical poly-L-lysine.
Wilcox KG, Dingle ME, Saha A, Hore MJA, Morozova S. Wilcox KG, et al. Soft Matter. 2022 Sep 14;18(35):6550-6560. doi: 10.1039/d2sm00921h. Soft Matter. 2022. PMID: 36039676
With increasing pH, we find an increase in l(p) from 2 nm to 15-21 nm because of alpha-helix formation. We performed dissipative particle dynamics (DPD) simulations and found a similar increase in l(p). While this l(p) is less than that predicted by molecular …
With increasing pH, we find an increase in l(p) from 2 nm to 15-21 nm because of alpha-helix formation. We performed dissipative part …
[(INDUCED MALARIA)].
Kondrashin AV, Baranova AM, Morozova LF, Guzeeva TM, Morozov EN, Stepanova EV. Kondrashin AV, et al. Med Parazitol (Mosk). 2017 Apr;(2):21-27. Med Parazitol (Mosk). 2017. PMID: 30721598 Russian.
In the USSR and then in the Russian Federation, sporadic cases of induced malaria (Plasniodium vivax, P.malariae, rarely P.falciparum) were notified (230 cases in 1958 to 1990 and only 5 in 1991 to 2016). ...
In the USSR and then in the Russian Federation, sporadic cases of induced malaria (Plasniodium vivax, P.malariae, rarely P.fal …
388 results